# Biogen Shares Rise After JPMorgan Upgrade and $300 Price Target

- URL: https://stocks.freetheai.org/news/biogen-shares-rise-after-jpmorgan-upgrade-and-300-price-target-9c11de
- Published: 2026-10-12T08:59:12Z
- Category: analyst_ratings; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:BIIB](https://stocks.freetheai.org/symbols/NASDAQ-BIIB)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Biogen Inc. (NASDAQ:BIIB) saw its stock rise after JPMorgan upgraded the pharmaceutical company from neutral to overweight and set a price target of $300. The new target represents a potential 33% increase from the prior closing price. Shares were up over 3% following the rating change.

The rating upgrade comes as analyst Christopher Schott highlighted a stronger long-term growth outlook and a promising lineup of drug pipeline catalysts anticipated in 2027. Biogen has experienced revenue pressure in its core multiple sclerosis business due to competition and pricing challenges, increasing its reliance on newer products such as Alzheimer's drug Leqembi to revive growth.

Investors are also following the company's progress in expanding beyond its primary neurology portfolio. Earlier this month, Biogen reported positive mid-stage study results showing durable skin symptom improvement for an experimental autoimmune drug. Overall Wall Street analyst consensus on the stock remains a Buy.

## Key points

- JPMorgan upgraded Biogen Inc. (NASDAQ:BIIB) from neutral to overweight with a $300 price target.
- The upgrade highlights expected drug pipeline catalysts coming in 2027 and an improved long-term growth outlook.
- Biogen faces revenue pressure in its legacy multiple sclerosis portfolio from competition and pricing challenges.
- The company recently reported positive mid-stage study results for an experimental autoimmune disease drug.

## Questions and answers

### Why did JPMorgan upgrade Biogen stock?

JPMorgan upgraded Biogen due to an improved long-term growth outlook and key drug pipeline catalysts expected in 2027.

### What is the new price target for Biogen?

JPMorgan set a price target of $300 for Biogen, which implies a 33% upside from the stock's previous closing price.

### What challenges is Biogen facing in its legacy business?

Biogen is experiencing pricing challenges and increased competition within its legacy multiple sclerosis drug portfolio.